This article studies the interaction between two individual decisions in the context of sexually transmitted diseases: on the one hand, the choice the of risk level, on the other hand, the decision to get tested. Our angle here is economic epidemiology, which aims at identifying the essential arbitrages that involve private decisions. Since testing opens access to treatments for a disease, it reduces the private cost of risk taking, all the more so when available treatments are more efficacious. From this, it stems that improvements in treatmentds can spur an increase in the risk level, by diminishing the cost associated with risk for those individuals who have opted for testing. An empirical analysis based on data from the San Francisco Stop Aids Project confirms this theoretical prediction. The apparition, during the year 1996, of new treatments against HIV coincided with an increaese in risky behavior within the tested population (test group) but not within the population that had not undertaken testing (control group).
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
Publisher Info
Paper provided by University of Toronto, Department of Economics in its series Working Papers with number
tecipa-210.
Cited by: (explanations, Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.)